Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 14, 2016 5:07 PM ET

Biotechnology

Company Overview of Reliance Life Sciences Pvt. Ltd.

Company Overview

Reliance Life Sciences Pvt. Ltd. operates as a life sciences company. Its activities include researching, developing, and marketing plasma proteins, biosimilars, and proteins; developing active pharmaceutical ingredients and formulations, such as oncology products, steroids, hormones, and peptides; offering services, which include regulatory toxicity studies, bioavailability, pharmacokinetics, cardiac safety, mass balance studies, phase I to IV clinical trial management and monitoring, data management and biostatistics, and medical writing; and providing regenerative medicine, which include embryonic stem cells, ocular stem cells, haematopoietic stem cells, skin and tissue engineering, and a...

Dhirubhai Ambani Life Sciences Centre

R-282, TTC Area of MIDC

Thane-Belapur Road

Rabale

Navi Mumbai,  400 701

India

Founded in 2001

Phone:

91 22 6767 8000

Fax:

91 22 6767 8099

Key Executives for Reliance Life Sciences Pvt. Ltd.

Chief Executive Officer and President
Age: 57
President of U S Operations
General Manager of Corporate Communications
Compensation as of Fiscal Year 2015.

Reliance Life Sciences Pvt. Ltd. Key Developments

Delhi High Court Places Temporary Injunction Preventing Sales of Reliance's Biosimilar Trastuzumab

The Indian Delhi High Court has issued a temporary injunction banning Reliance (India) from launching a "biosimilar" version of Roche (Switzerland)'s breast cancer drug Herceptin (trastuzumab). The injunction follows a petition filed by Roche, which argues that Reliance's product is similar to Herceptin. The two companies have now been requested to submit written submissions within two weeks before the court is to hear the case.

Torrent Pharmaceuticals Ltd Enters into an Exclusive Licensing Agreement with Reliance Life Sciences

Torrent Pharmaceuticals Ltd. has entered into an exclusive licensing agreement with Reliance Life Sciences for marketing three biosimilars in the Indian market. Torrent Pharmaceuticals informed that Rituximab, Adalimumab and Cetuximab will be developed by Reliance Life Sciences and supplied to Torrent Pharma after obtaining all necessary regulatory approvals. Torrent Pharma will be the only company to market these biosimilars in India other than Reliance Life Sciences. According to the terms of agreement, Reliance Life Sciences will manufacture these products at its facility in Navi Mumbai and supply to Torrent Pharma for 10 years.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Reliance Life Sciences Pvt. Ltd., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.